Effect of Saroglitazar on Glycemic Status: A Meta-analysis
Sandhiya Selvarajan1, Anandabaskar Nishanthi2, Ilanthamizhan Jayakumar3
1Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, IND.
Cureus
|January 14, 2026
Summary
Saroglitazar significantly reduces HbA1c, fasting blood sugar, and post-prandial blood sugar in patients with type 2 diabetes or prediabetes and dyslipidemia. This meta-analysis confirms its efficacy in managing glycemic control and lipid profiles.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Diabetic dyslipidemia is a common complication of type 2 diabetes and prediabetes.
- Effective management of glycemic and lipid profiles is crucial for reducing cardiovascular risk in these patients.
Purpose of the Study:
- To systematically review and meta-analyze the glycemic effects of saroglitazar.
- To assess saroglitazar's impact on HbA1c, fasting blood sugar (FBS), and post-prandial blood sugar (PPBS) levels.
- To evaluate changes in lipid profiles and adverse drug reactions associated with saroglitazar treatment.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials and observational studies.
- Searched PubMed and Google Scholar databases up to December 2023.
- Assessed risk of bias using ROB2.
- Analyzed primary outcomes (glycemic parameters) and secondary outcomes (lipid profile).
Main Results:
- Saroglitazar treatment led to significant reductions in FBS (-30.16), PPBS (-69.09), and HbA1c (-0.93).
- Significant reductions were observed in total cholesterol, low-density lipoprotein, and very-low-density lipoprotein levels.
- High-density lipoprotein levels showed improvement with saroglitazar treatment.
Conclusions:
- Saroglitazar effectively reduces HbA1c, FBS, and PPBS levels in patients with diabetic dyslipidemia.
- The drug demonstrates a positive impact on lipid profiles, improving overall cardiovascular risk factors.
- The findings support saroglitazar as a beneficial therapeutic option for managing type 2 diabetes or prediabetes with dyslipidemia.
Keywords:
diabetes type 2diabetic dyslipidemiaglycosylated haemoglobin (hba1c)lipid-profilesaroglitazarMore Related Videos
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.6K
10:31An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
Published on: April 20, 2018
11.1K
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
582
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
582
01:06Oral Hypoglycemic Agents: Glinides
595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
522
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
522
01:23Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
01:17Oral Hypoglycemic Agents: Sulfonylureas
770
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
770
01:24Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840